SG11201402396XA - Immunogenic treatment of cancer - Google Patents
Immunogenic treatment of cancerInfo
- Publication number
- SG11201402396XA SG11201402396XA SG11201402396XA SG11201402396XA SG11201402396XA SG 11201402396X A SG11201402396X A SG 11201402396XA SG 11201402396X A SG11201402396X A SG 11201402396XA SG 11201402396X A SG11201402396X A SG 11201402396XA SG 11201402396X A SG11201402396X A SG 11201402396XA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- immunogenic treatment
- immunogenic
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Radiology & Medical Imaging (AREA)
- Communicable Diseases (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1120779.2A GB201120779D0 (en) | 2011-12-02 | 2011-12-02 | Cancer therapy |
| PCT/GB2012/052992 WO2013079980A1 (en) | 2011-12-02 | 2012-12-03 | Immunogenic treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201402396XA true SG11201402396XA (en) | 2014-10-30 |
Family
ID=45509083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201402396XA SG11201402396XA (en) | 2011-12-02 | 2012-12-03 | Immunogenic treatment of cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20140356397A1 (en) |
| EP (1) | EP2785361B1 (en) |
| JP (1) | JP6085611B2 (en) |
| KR (1) | KR20140097419A (en) |
| CN (1) | CN104023733A (en) |
| AU (1) | AU2012343536B2 (en) |
| BR (1) | BR112014012880A2 (en) |
| CA (1) | CA2857429A1 (en) |
| GB (1) | GB201120779D0 (en) |
| IL (1) | IL232890A0 (en) |
| IN (1) | IN2014MN00955A (en) |
| MX (1) | MX2014006511A (en) |
| RU (1) | RU2014121335A (en) |
| SG (1) | SG11201402396XA (en) |
| WO (1) | WO2013079980A1 (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11963716B2 (en) | 2010-07-19 | 2024-04-23 | Emblation Limited | Apparatus and method for the treatment of dermatological diseases or conditions |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| GB201308325D0 (en) * | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| EP3077041A4 (en) * | 2013-12-05 | 2017-08-23 | Rfemb Holdings LLC | Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb) |
| GB201322725D0 (en) * | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| CA2975123A1 (en) * | 2015-01-30 | 2016-08-04 | Rfemb Holdings, Llc | Radio frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue |
| AU2016281765B2 (en) * | 2015-06-24 | 2022-06-16 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| RU2596505C1 (en) * | 2015-07-02 | 2016-09-10 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) | Method of treating oncological patients with cytotoxic lymphocytes |
| US10478194B2 (en) | 2015-09-23 | 2019-11-19 | Covidien Lp | Occlusive devices |
| CA3011460A1 (en) | 2016-01-15 | 2017-07-20 | Rfemb Holdings, Llc | Immunologic treatment of cancer |
| JP7175437B2 (en) * | 2016-04-14 | 2022-11-21 | フェルドリヒ・カロ・ルイズ・アーべー | Apparatus used for radiotherapy |
| SG11201909107YA (en) | 2017-03-28 | 2019-11-28 | Emblation Ltd | Stenosis treatment |
| WO2019018813A1 (en) | 2017-07-21 | 2019-01-24 | Varian Medical Systems, Inc. | Methods of use of ultra-high dose rate radiation and therapeutic agents |
| RU2664597C1 (en) * | 2017-12-12 | 2018-08-21 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) | Method of combined treatment of patients with primarily operable and locally advanced inoperable breast cancer |
| CA3119915A1 (en) | 2018-12-03 | 2020-06-11 | Eric Steven BURAK | Radioimmunoconjugates and dna damage and repair inhibitor combination therapy |
| CA3162969A1 (en) * | 2019-12-27 | 2021-07-01 | Kunihiko Kobayashi | Cancer treatment method and medicine |
| EP4376945A1 (en) * | 2021-07-27 | 2024-06-05 | Immodulon Therapeutics Limited | A mycobacterium for use in cancer therapy |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5207223A (en) | 1990-10-19 | 1993-05-04 | Accuray, Inc. | Apparatus for and method of performing stereotaxic surgery |
| DE69126668T2 (en) * | 1990-11-08 | 1997-10-23 | Univ London | MYCOBACTERIUM AS ADJUVANS FOR ANTIGENS |
| US5458125A (en) | 1994-01-28 | 1995-10-17 | Board Of Directors Of The Leland Standford Jr. University | Treatment planning method and apparatus for radiosurgery and radiation therapy |
| CA2369542C (en) | 1999-04-23 | 2009-10-27 | Qlt Inc. | Immuno-adjuvant pdt treatment of metastatic tumors |
| US20020022032A1 (en) | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
| AU2002353366A1 (en) * | 2001-12-10 | 2003-06-23 | Bakulesh Mafatlal Khamar | The process of manufacturing a pharmaceutical composition useful for management of cancer |
| SI2206517T1 (en) | 2002-07-03 | 2023-12-29 | Ono Pharmaceutical Co., Ltd. | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| CA2492160A1 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Mesothelin vaccines and model systems |
| EP1937303A4 (en) | 2005-10-21 | 2009-11-18 | Med College Georgia Res Inst | The induction of indoleamine 2,3-dioxygenase in dendritic cells by tlr ligands and uses thereof |
| US20080318252A1 (en) | 2007-04-23 | 2008-12-25 | Scott Kachlany | Rapid assay to test anti-cancer drugs under physiological conditions |
| GB0526033D0 (en) * | 2005-12-21 | 2006-02-01 | Bioeos Ltd | Method |
| EP2010216A4 (en) * | 2006-03-24 | 2010-06-09 | Donald L Morton | Mycobacterial immunotherapy for cancer treatment |
| WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
| PL2170959T3 (en) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| RS53782B1 (en) * | 2008-10-01 | 2015-06-30 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers |
| US8367075B2 (en) | 2010-07-02 | 2013-02-05 | Indian Institute Of Science | Synergistic combination and method thereof |
| US9114158B2 (en) * | 2011-03-09 | 2015-08-25 | The Johns Hopkins University | Compounds and methods of use in ablative radiotherapy |
| EP2723381A4 (en) | 2011-06-21 | 2015-03-18 | Univ Johns Hopkins | Focused radiation for augmenting immune-based therapies against neoplasms |
| GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
| EP2620159A1 (en) | 2012-01-24 | 2013-07-31 | Institut Pasteur | Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria |
| WO2013114367A2 (en) | 2012-02-01 | 2013-08-08 | Compugen Ltd. | C10rf32 antibodies, and uses thereof for treatment of cancer |
| US8617520B2 (en) | 2012-02-15 | 2013-12-31 | Immodulon Therapeutics Limited | Cancer therapy |
| GB201308325D0 (en) | 2013-05-09 | 2013-06-19 | Immodulon Therapeutics Ltd | Cancer Therapy |
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| EP4070818A3 (en) | 2014-01-06 | 2023-01-11 | The Trustees of the University of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| US10975112B2 (en) | 2015-06-16 | 2021-04-13 | Hangzhou Dac Biotech Co., Ltd. | Linkers for conjugation of cell-binding molecules |
| AU2016281765B2 (en) | 2015-06-24 | 2022-06-16 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
| JP2021529741A (en) | 2018-06-25 | 2021-11-04 | イモデュロン セラピューティクス リミテッド | Cancer treatment |
-
2011
- 2011-12-02 GB GBGB1120779.2A patent/GB201120779D0/en not_active Ceased
-
2012
- 2012-12-03 EP EP12799260.0A patent/EP2785361B1/en active Active
- 2012-12-03 MX MX2014006511A patent/MX2014006511A/en unknown
- 2012-12-03 JP JP2014543984A patent/JP6085611B2/en active Active
- 2012-12-03 RU RU2014121335A patent/RU2014121335A/en unknown
- 2012-12-03 CN CN201280059421.0A patent/CN104023733A/en active Pending
- 2012-12-03 KR KR1020147016935A patent/KR20140097419A/en not_active Application Discontinuation
- 2012-12-03 BR BR112014012880A patent/BR112014012880A2/en not_active IP Right Cessation
- 2012-12-03 US US14/361,992 patent/US20140356397A1/en not_active Abandoned
- 2012-12-03 WO PCT/GB2012/052992 patent/WO2013079980A1/en active Application Filing
- 2012-12-03 CA CA2857429A patent/CA2857429A1/en not_active Abandoned
- 2012-12-03 SG SG11201402396XA patent/SG11201402396XA/en unknown
- 2012-12-03 AU AU2012343536A patent/AU2012343536B2/en active Active
- 2012-12-03 IN IN955MUN2014 patent/IN2014MN00955A/en unknown
-
2014
- 2014-05-29 IL IL232890A patent/IL232890A0/en unknown
-
2018
- 2018-12-19 US US16/225,028 patent/US11318193B2/en active Active
-
2020
- 2020-06-30 US US16/916,194 patent/US11554166B2/en active Active
-
2023
- 2023-01-13 US US18/154,177 patent/US20230149525A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB201120779D0 (en) | 2012-01-11 |
| IL232890A0 (en) | 2014-07-31 |
| US20230149525A1 (en) | 2023-05-18 |
| WO2013079980A1 (en) | 2013-06-06 |
| EP2785361A1 (en) | 2014-10-08 |
| JP2014533743A (en) | 2014-12-15 |
| AU2012343536B2 (en) | 2017-08-24 |
| CA2857429A1 (en) | 2013-06-06 |
| US11318193B2 (en) | 2022-05-03 |
| JP6085611B2 (en) | 2017-02-22 |
| IN2014MN00955A (en) | 2015-04-24 |
| BR112014012880A2 (en) | 2017-06-13 |
| US20140356397A1 (en) | 2014-12-04 |
| KR20140097419A (en) | 2014-08-06 |
| EP2785361B1 (en) | 2018-11-28 |
| US11554166B2 (en) | 2023-01-17 |
| RU2014121335A (en) | 2016-01-27 |
| NZ624994A (en) | 2016-10-28 |
| US20200338181A1 (en) | 2020-10-29 |
| MX2014006511A (en) | 2014-12-05 |
| AU2012343536A1 (en) | 2014-06-05 |
| US20190224294A1 (en) | 2019-07-25 |
| CN104023733A (en) | 2014-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL232890A0 (en) | Immunogenic treatment of cancer | |
| HK1202253A1 (en) | Combination treatment of cancer | |
| HK1201413A1 (en) | Treatment of breast cancer | |
| EP2752198A4 (en) | Vaccine preparation for cancer treatment | |
| EP2788378A4 (en) | Combination therapy for treatment of cancer | |
| HK1214128A1 (en) | Treatment of cancer | |
| IL228430A0 (en) | Treatment of cancer | |
| HK1205254A1 (en) | Methods of treatment of cancer | |
| HK1206642A1 (en) | Method of adjuvant cancer treatment | |
| GB201217892D0 (en) | Treatment of cancer | |
| HK1204956A1 (en) | Treatment of cancer | |
| IL237229A0 (en) | Methods for treatment of cancer using lipoplatin | |
| GB201217890D0 (en) | Treatment of cancer | |
| GB201121783D0 (en) | Treatment of cancer | |
| GB201121791D0 (en) | Combination treatment of cancer | |
| EP2750691A4 (en) | Srpx for treatment of cancer | |
| AU2012905667A0 (en) | Vaccines for treatment of cancer | |
| GB201208296D0 (en) | Treatment of cancer | |
| GB201017354D0 (en) | Treatment of cancer |